ReceptivaDxTM is a new and improved non-surgical test for endometrial receptivity that provides enhanced screening for ALL stages of endometriosis and other conditions that interfere with implantation. This is the first test for endometriosis with high sensitivity and specificity (96%), especially useful in women with unexplained IVF failure or infertility. While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDxTM can accurately detect inflammatory conditions on the uterine lining likely to cause implantation issues
The test specifically identifies BCL6, a gene repressor biomarker that is present in the setting of inflammation. BCL6 is dramatically over-expressed in women with endometriosis, making it a likely candidate for the cause of progesterone resistance that contributes to implantation problems (read blog post). Progesterone is required for normal pregnancy, so a protein that interferes with progesterone action would explain much about the problems encountered in women with endometriosis.